SCHEMBL24933189

SCHEMBL24933189

COCc1ccc(-c2cc(C(N)=O)c(=O)[nH]c2C(F)(F)F)cc1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 8/20 0.39
HSD17B2 P37059 8/20 0.39
CDK5 Q00535 1/20 0.37
CDK5R1 Q15078 1/20 0.37
KCNH2 Q12809 1/20 0.36
ATM Q13315 1/20 0.36
MPL P40238 1/20 0.35
RAB9A P51151 1/20 0.35
ACVR1 Q04771 1/20 0.33
MAOB P27338 1/20 0.33
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
RXRG P48443 1/20 0.33
MAPK8 P45983 1/20 0.33
BTK Q06187 1/20 0.32
PARP1 P09874 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24933637 0.87 MAOB (0.44) RAB9AMAOBPARP1
SCHEMBL24933771 0.87 IKBKB (0.42) HSD17B1HSD17B2CDK5CDK5R1RXRA
SCHEMBL24933053 0.84 KDM4E (0.44) HSD17B1HSD17B2PARP1
SCHEMBL24932956 0.84 FYN (0.45) HSD17B1HSD17B2PARP1
SCHEMBL24933605 0.84 HSD17B2 (0.41) HSD17B1HSD17B2PARP1
SCHEMBL24933797 0.84 PARP1 (0.44) HSD17B1HSD17B2MAPK8PARP1
SCHEMBL24933671 0.84 MAOB (0.56) MAOB
SCHEMBL24933847 0.83 CHEK1 (0.46) HSD17B1HSD17B2PARP1
SCHEMBL24933359 0.83 HSD17B2 (0.50) HSD17B1HSD17B2ATMBTK
SCHEMBL24933312 0.81 BTK (0.42) HSD17B1HSD17B2CDK5MAPK8BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP claimed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN claimed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO claimed
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed